Discussion on the selection of ACEI and ARB for the patients with COVID-19 and hypertension from ACE2.

With the wide spread of COVID-19, some studies have confirmed that novel coronavirus enters the cell through the binding of spike protein and ACE2 protein, which has the risk of causing the virus to enter the cell to accelerate its transmission. ACEI and ARB are the key drugs for the treatment of hypertension and are widely used in clinic. They are good for ventricular and vascular remodeling in patients with hypertension, coronary heart disease and heart failure. ACEI and ARB drugs may increase the expression of ACE2 in lung tissue and increase the risk of aggravation of the disease. According to the advice of hypertension experts: for mild ordinary COVID-19 patients with hypertension, we can consider discontinuing ACEI and ARB drugs, while for severe COVID-19 patients with hypertension, ACEI and ARB drugs should be stopped immediately. During the discontinuation period, temporary replacement therapy with diuretics, dipine and vasodilatation hypotensive drugs can be considered.